Skip to main content

Table 1 Sample demographic and clinical characteristics, overall and by retention in care status

From: Barriers and facilitators to patient retention in HIV care

Characteristica

Total

Retained in careh

Not retained in careh

(N = 51)

(N = 25)

(N = 26)

Age (years)b

18-29

4 (8 %)

1 (4 %)

3 (12 %)

30-39

11 (22 %)

2 (8 %)

9 (35 %)

40-49

18 (35 %)

10 (40 %)

8 (31 %)

≥50

18 (35 %)

12 (48 %)

6 (23 %)

Sex

Male

27 (53 %)

19 (76 %)

8 (31 %)

Female

24 (47 %)

6 (24 %)

18 (69 %)

Race/Ethnicity

White

6 (12 %)

3 (12 %)

3 (12 %)

Black

41 (80 %)

21 (84 %)

20 (77 %)

Hispanic

3 (6 %)

1 (4 %)

2 (8 %)

Other

1 (2 %)

0 (0 %)

1 (4 %)

HIV risk factorc

MSM

13 (26 %)

8 (32 %)

5 (19 %)

Heterosexual

35 (69 %)

14 (56 %)

21 (81 %)

IDU

3 (6 %)

3 (12 %)

0 (0 %)

Insuranced

Private

4 (8 %)

1 (4 %)

3 (12 %)

Medicaid

34 (67 %)

17 (68 %)

17 (65 %)

Medicare

10 (18 %)

6 (24 %)

4 (15 %)

Uninsured

3 (6 %)

1 (4 %)

2 (8 %)

ART regimene

PI

29 (57 %)

16 (64 %)

13 (50 %)

NNRTI

15 (29 %)

7 (28 %)

8 (31 %)

Integrase

5 (10 %)

2 (8 %)

3 (12 %)

Not on ART

2 (4 %)

0 (0 %)

2 (8 %)

CD4 cell count (cell/mm3)f

≤ 200

8 (16 %)

6 (24 %)

2 (8 %)

201-350

8 (16 %)

2 (8 %)

6 (23 %)

351-500

8 (16 %)

4 (16 %)

4 (15 %)

> 500

27 (53 %)

13 (52 %)

14 (54 %)

Viral suppressiong

Suppressed

29 (57 %)

17 (68 %)

12 (46 %)

Not suppressed

22 (43 %)

8 (32 %)

14 (54 %)

  1. Abbreviations: ART antiretroviral therapy, MSM men who have sex with men, IDU injection drug use, PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor
  2. aCharacteristics and values within the 12-month period prior to interview date
  3. bAge on the date of interview
  4. cPatients who had IDU in combination with another risk factor (e.g. MSM, HET) were classified as IDU
  5. dPatients with both Medicare and Medicaid were grouped as Medicare
  6. ePatients were considered to be on ART if they concomitantly received ≥ 3 antiretroviral drugs (excluding ritonavir) during the 12-month period prior to the interview date. ART regimen prescribed closest to the interview date was grouped using the following hierarchy: (1) PI-based; (2) NNRTI-based; and (3) integrase inhibitor-based
  7. fCD4 cell count closest to the date of interview
  8. gHIV viral suppression was categorized as suppressed (HIV-1 RNA ≤ 400 copies/mL) and not suppressed (HIV-1 RNA > 400 copies/mL) based on the median value in the 12-month period before the interview date
  9. hRetention in care was defined as completing 2 or more primary HIV care visits separated by ≥ 90 days in the 12-month period prior to the interview date